Single Session MRI-Guided Stereotactic Body Radiation Therapy for Liver Metastases From Colorectal Cancer

What this Trial Is About

Researchers are evaluating a high-dose, single-session, MRI-guided stereotactic body radiation therapy SBRT for people with colorectal cancer that has spread to the liver. This study aims to see how well this treatment can stop liver metastases from growing or spreading and to track any side effects. They also want to identify features in MRI images that might predict how well patients respond to the therapy. Participants will first undergo a simulation scan using a special MRI contrast agent Gd-EOB-DTPA to help plan treatment with minimal margins. About ten days later, they will receive a single high dose of 40 Gy radiation delivered by the Elekta Unity machine, guided and adapted in real time by the enhanced MRI. This approach focuses radiation precisely on liver tumors while sparing healthy tissue. During the study, participants will have assessments including the initial MRI scan for planning, treatment delivery with image guidance, and follow-up to monitor tumor control and side effects. The main outcome measured is the local control rate of liver metastases one year after treatment. Researchers will also closely monitor liver function and any adverse effects. The total participation duration extends through at least one year of follow-up after treatment.

A Study of Single Fraction Stereotactic Body Radiation Therapy (SBRT) Guided by Magnetic Resonance Imaging (MRI) in People With Liver Metastasis From Colorectal Cancer